Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146 is a research paper published in Journal for ImmunoTherapy of Cancer (2024). On theSindex it has a DataRank of 0.783. It has been cited 19 times, with 18 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.449
From this paper's citation signal
Citation Network Contribution
0.333
From 11 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 18 citers.
Eisai Inc., Nutley, NJ, USA
Grant: N/A
NCI NIH HHS
Grant: P30 CA008748
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
FWCI
8.12
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals